Beverly A. Teicher

25.0k total citations · 6 hit papers
396 papers, 18.1k citations indexed

About

Beverly A. Teicher is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Beverly A. Teicher has authored 396 papers receiving a total of 18.1k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Molecular Biology, 176 papers in Oncology and 124 papers in Cancer Research. Recurrent topics in Beverly A. Teicher's work include Cancer, Hypoxia, and Metabolism (94 papers), Cancer therapeutics and mechanisms (43 papers) and Angiogenesis and VEGF in Cancer (39 papers). Beverly A. Teicher is often cited by papers focused on Cancer, Hypoxia, and Metabolism (94 papers), Cancer therapeutics and mechanisms (43 papers) and Angiogenesis and VEGF in Cancer (39 papers). Beverly A. Teicher collaborates with scholars based in United States, Australia and Japan. Beverly A. Teicher's co-authors include Simon P. Fricker, Sylvia A. Holden, Terence S. Herman, Alan C. Sartorelli, John S. Lazo, Anish Thomas, Christopher M. Rose, Gulshan Ara, Ravi Chari and Raffit Hassan and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Beverly A. Teicher

380 papers receiving 17.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

2010 1.2k citations Beverly A. Teicher et al. Clinical Cancer Research profile →
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

2013 592 citations Junko Murai, Shar-yin N. Huang et al. Molecular Cancer Therapeutics profile →
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs

1988 524 citations Beverly A. Teicher et al. profile →
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.

1981 453 citations Beverly A. Teicher et al. PubMed profile →
Antibody–drug conjugates for cancer therapy

2016 450 citations Beverly A. Teicher et al. profile →
Cancer treatments: Past, present, and future

2024 192 citations Beverly A. Teicher et al. profile →

Peers

Countries citing papers authored by Beverly A. Teicher

Since Specialization

Citations

This map shows the geographic impact of Beverly A. Teicher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beverly A. Teicher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beverly A. Teicher more than expected).

Fields of papers citing papers by Beverly A. Teicher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beverly A. Teicher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beverly A. Teicher. The network helps show where Beverly A. Teicher may publish in the future.

Co-authorship network of co-authors of Beverly A. Teicher

This figure shows the co-authorship network connecting the top 25 collaborators of Beverly A. Teicher. A scholar is included among the top collaborators of Beverly A. Teicher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beverly A. Teicher. Beverly A. Teicher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types 2025 ·Cancer Research Communications ·(unknown), Thomas S. Dexheimer, Nathan P. Coussens, (unknown), Raymond G. Fox, Samantha B. Kemp, Poorva Juneja, Joel Morris, Melinda G. Hollingshead, Naoko Takebe, James H. Doroshow, Beverly A. Teicher	0
2	HTS384 NCI60: The Next Phase of the NCI60 Screen 2024 ·Cancer Research ·Mark W. Kunkel, Nathan P. Coussens, Joel Morris, Ronald C. Taylor, Thomas S. Dexheimer, Eric M. Jones, James H. Doroshow, Beverly A. Teicher	11
3	In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts 2024 ·Experimental Hematology ·(unknown), Kathryn L. Evans, (unknown), (unknown), Christopher M. Smith, Eric J. Earley, Stephen W. Erickson, (unknown), Carol J. Bult, Beverly A. Teicher, Charles E. de Bock, Malcolm A. Smith, Richard B. Lock	0
4	Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma 2022 ·Cancer Research Communications ·Kateryna Krytska, (unknown), Jennifer Pogoriler, Daniel Martínez, Komal S. Rathi, Alvin Farrel, Esther R. Berko, (unknown), (unknown), Nathan M. Kendsersky, Stephen W. Erickson, Beverly A. Teicher, Kumiko Isse, Laura R. Saunders, Malcolm A. Smith, John M. Maris, Yaël P. Mossé	5
5	The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission 2022 ·Blood Cancer Discovery ·Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla‐Favera, Chi V. Dang, Luis A. Díaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michaël Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher	0
6	F-aza-T-dCyd (NSC801845), a Novel Cytidine Analog, in Comparative Cell Culture and Xenograft Studies with the Clinical Candidates T-dCyd, F-T-dCyd, and Aza-T-dCyd 2021 ·Molecular Cancer Therapeutics ·Joel Morris, Donn G. Wishka, Omar D. Lopez, (unknown), (unknown), (unknown), Suzanne Borgel, (unknown), John Carter, Howard Stotler, Mark W. Kunkel, Jerry M. Collins, Melinda G. Hollingshead, Beverly A. Teicher	7
7	ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium 2020 ·Molecular Cancer Therapeutics ·Pooja Hingorani, Michael Roth, (unknown), Wendong Zhang, Jonathan Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory J. Gatto, Malcolm A. Smith, E. Anders Kolb, Richard Görlick	23
8	Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks 2018 ·Molecular Cancer Therapeutics ·Aashish Soni, Fanghua Li, You Wang, Martha Grabos, (unknown), (unknown), (unknown), Mansoor M. Ahmed, C. Norman Coleman, Beverly A. Teicher, Richard Piekarz, Dian Wang, George Iliakis	17
9	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Ai Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell, John T. Poirier, Charles M. Rudin	261
10	Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression 2015 ·Molecular Cancer Therapeutics ·Beverly A. Teicher, Eric C. Polley, Mark W. Kunkel, David M. Evans, Thomas Silvers, René Delosh, Julie Laudeman, (unknown), Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, Joel Morris	55
11	Anti-Endosialin Antibody–Drug Conjugate: Potential in Sarcoma and Other Malignancies 2015 ·Molecular Cancer Therapeutics ·Cécile Rouleau, Diego A. Gianolio, Robert Smale, Stephanie Roth, (unknown), Jay Harper, Kenneth Munroe, (unknown), Bruce Horten, Steven M. Schmid, Beverly A. Teicher	34
12	Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib breakdown → 2013 ·Molecular Cancer Therapeutics ·Junko Murai, Shar-yin N. Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly A. Teicher, James H. Doroshow, Yves Pommier	592
13	sFLT01: A Novel Fusion Protein with Antiangiogenic Activity 2011 ·Molecular Cancer Therapeutics ·Rebecca G. Bagley, Leslie Kurtzberg, William Weber, Tri‐Hung Nguyen, Stéphanie Roth, (unknown), Min Yao, Brenda Richards, Mindy Zhang, Peter Pecháň, (unknown), Abraham Scaria, Johanne Kaplan, Beverly A. Teicher	20
14	Molecular and Cellular Pharmacology of the Novel Noncamptothecin Topoisomerase I Inhibitor Genz-644282 2011 ·Molecular Cancer Therapeutics ·(unknown), Thomas S. Dexheimer, Beverly A. Teicher, Yves Pommier	31
15	Tumor Models in Cancer Research 2010 ·Humana Press eBooks ·Beverly A. Teicher	66
16	Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias 2009 ·Clinical Cancer Research ·Constantine S. Mitsiades, Cécile Rouleau, Cinara Echart, Krishna Menon, Beverly A. Teicher, Maria Distaso, Antonio Palumbo, Mario Boccadoro, Kenneth C. Anderson, Massimo Iacobelli, Paul G. Richardson	46
17	Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma 2008 ·Clinical Cancer Research ·Cécile Rouleau, (unknown), William Weber, Robert Smale, Leslie Kurtzberg, James T. Mascarello, Carol Berger, (unknown), Rebecca G. Bagley, Nakayuki Honma, Kazumasa Hasegawa, Isao Ishida, Shiro Kataoka, Beth L. Thurberg, (unknown), Bruce Horten, Glenn A. Miller, Beverly A. Teicher	86
18	Antiangiogenic Agents in Cancer Therapy 1999 ·Humana Press eBooks ·Beverly A. Teicher	102
19	Anticancer Drug Development Guide 1997 ·Humana Press eBooks ·Beverly A. Teicher	116
20	Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. 1989 ·PubMed ·(unknown), Beverly A. Teicher, Thomas C. Shea, Sylvia A. Holden, Kristina W. Rosbe, Antoine Al-Achi, W. David Henner	82

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact